Role of adipose tissue in haemostasis, coagulation and fibrinolysis

Obesity Reviews

Volumn 10, Issue 5, 2009, Pages 554-563

  Faber, D R ^a   De Groot, Ph G ^a   Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adipose tissue; Coagulation; Haemostasis; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CYTOKINE; FATTY ACID; FIBRINOGEN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADIPOSE TISSUE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LIVER; NONHUMAN; OBESITY; PORTAL VEIN BLOOD FLOW; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADIPOSE TISSUE; ANIMALS; BLOOD PLATELETS; FIBRINOLYSIS; HUMANS; LIVER;

EID: 69449096498     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2009.00593.x     Document Type: Review

References (70)

1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007 132 : 2087 2102.
2. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006 116 : 1793 1801.
3. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007 56 : 1010 1013.
4. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008 168 : 1678 1683.
5. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr., Razak F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005 366 : 1640 1649.
6. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995 269 : 546 549.
7. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001 104 : 3052 3056.
8. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001 108 : 1533 1540.
9. Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004 24 : 2196 2201.
10. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999 48 : 426 429.
11. Dellas C, Schafer K, Rohm IK, Lankeit M, Leifheit M, Loskutoff DJ, Hasenfuss G, Konstantinides SV. Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb Haemost 2007 98 : 1063 1071.
12. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006 26 : 224 230.
13. Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Yamane T, Hino M, Shioi A, Nishizawa Y. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006 188 : 190 195.
14. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007 558 : 7 13.
15. Riba R, Hughes CE, Graham A, Watson SP, Naseem KM. Globular adiponectin induces platelet activation through the collagen receptor GPVI-Fc receptor gamma chain complex. J Thromb Haemost 2008 6 : 1012 1020.
16. Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappa B and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007 56 : 804 808.
17. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988 37 : 780 786.
18. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002 16 : 35 40.
19. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007 357 : 2482 2494.
20. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A 1998 95 : 7591 7596.
21. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003 9 : 458 462.
22. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001 98 : 3353 3358.
23. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E, Schernthaner G. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003 11 : 950 956.
24. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003 107 : 973 977. (Pubitemid 36258719)
25. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006 55 : 202 208.
26. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007 92 : 4352 4358.
27. Napoleone E, Di Santo A, Amore C, Baccante G, Di Febbo C, Porreca E, De Gaetano G, Donati MB, Lorenzet R. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007 5 : 1462 1468.
28. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003 89 : 601 609.
29. Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Lee HS. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: veterans affairs cooperative study in type II diabetes mellitus. Arch Intern Med 1998 158 : 2485 2490. (Pubitemid 28555508)
30. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The factor VIII acute phase response requires the participation of NF-kappa B and C/EBP. Thromb Haemost 2000 84 : 216 222.
31. Mitropoulos KA, Miller GJ, Reeves BE, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989 76 : 203 208.
32. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991 44 : 139 143.
33. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996 97 : 37 46.
34. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 88 : 1346 1353.
35. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996 7 : 813 817.
36. Scelles V, Raccah D, Alessi MC, Vialle JM, Juhan-Vague I, Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab 1992 18 : 38 42.
37. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998 41 : 65 71.
38. He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 2003 35 : 178 182.
39. Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract 2006 73 : 150 157.
40. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006 49 : 744 747.
41. Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med 2000 6 : 680 692.
42. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005 54 : 220 226.
43. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De SF, Cuscito M, De FM, Memeo V, Neri V, Cignarelli M, Giorgino R, Giorgino F. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 2006 55 : 952 961.
44. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998 18 : 1 6.
45. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 1999 96 : 6902 6907.
46. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000 20 : 1682 1687.
47. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007 56 : 901 911.
48. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006 341 : 549 556.
49. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007 455 : 479 492. (Pubitemid 47624196)
50. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000 20 : 2511 2518.
51. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002 87 : 660 665.
52. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003 101 : 4844 4846.
53. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005 15 : 265 268.
54. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003 1 : 791 797.
55. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000 165 : 1053 1058.
56. Christiaens V, Scroyen I, Lijnen HR. Role of proteolysis in development of murine adipose tissue. Thromb Haemost 2008 99 : 290 294.
57. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002 67 : 92 98.
58. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008 121 : 535 542.
59. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008 6 : 1198 1206.
60. Busam KJ, Bauer TM, Bauer J, Gerok W, Decker K. Interleukin-6 release by rat liver macrophages. J Hepatol 1990 11 : 367 373.
61. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005 11 : 183 190.
62. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar HA, Bedossa P, Guerre-Millo M, Clement K. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006 55 : 1554 1561.
63. Wang Z, Lv J, Zhang R, Zhu Y, Zhu D, Sun Y, Zhu J, Han X. Co-culture with fat cells induces cellular insulin resistance in primary hepatocytes. Biochem Biophys Res Commun 2006 345 : 976 983.
64. Zhou L, Sell H, Eckardt K, Yang Z, Eckel J. Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBS Lett 2007 581 : 4303 4308.
65. van der PD, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008 48 : 449 457.
66. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006 14 (Suppl. 1 16S 19S.
67. Clement S, Juge-Aubry C, Sgroi A, Conzelmann S, Pazienza V, Pittet-Cuenod B, Meier CA, Negro F. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008 48 : 799 807.
68. Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. World J Gastroenterol 2001 7 : 710 712.
69. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De SG. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 1996 76 : 69 73.
70. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003 23 : 1262 1268.